GRI Bio Statistics
Total Valuation
GRI Bio has a market cap or net worth of $788,037. The enterprise value is -$2.38 million.
Important Dates
The last earnings date was Thursday, May 15, 2025, before market open.
Earnings Date | May 15, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
GRI Bio has 525,358 shares outstanding.
Current Share Class | 525,358 |
Shares Outstanding | 525,358 |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | +7.02% |
Owned by Insiders (%) | 0.09% |
Owned by Institutions (%) | 0.90% |
Float | 524,755 |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 0.65 |
P/TBV Ratio | 0.65 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.41, with a Debt / Equity ratio of 0.09.
Current Ratio | 1.41 |
Quick Ratio | 1.18 |
Debt / Equity | 0.09 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -467.95% and return on invested capital (ROIC) is -275.36%.
Return on Equity (ROE) | -467.95% |
Return on Assets (ROA) | -136.04% |
Return on Invested Capital (ROIC) | -275.36% |
Return on Capital Employed (ROCE) | -743.55% |
Revenue Per Employee | n/a |
Profits Per Employee | -$2.82M |
Employee Count | 4 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -98.31% in the last 52 weeks. The beta is -2.22, so GRI Bio's price volatility has been lower than the market average.
Beta (5Y) | -2.22 |
52-Week Price Change | -98.31% |
50-Day Moving Average | 3.17 |
200-Day Moving Average | 8.73 |
Relative Strength Index (RSI) | 34.15 |
Average Volume (20 Days) | 293,173 |
Short Selling Information
The latest short interest is 104,998, so 19.99% of the outstanding shares have been sold short.
Short Interest | 104,998 |
Short Previous Month | 251,565 |
Short % of Shares Out | 19.99% |
Short % of Float | 20.01% |
Short Ratio (days to cover) | 0.11 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -9.39M |
Pretax Income | -12.77M |
Net Income | -11.28M |
EBITDA | -9.39M |
EBIT | -9.39M |
Earnings Per Share (EPS) | -$36.39 |
Full Income Statement Balance Sheet
The company has $3.28 million in cash and $108,000 in debt, giving a net cash position of $3.17 million or $6.04 per share.
Cash & Cash Equivalents | 3.28M |
Total Debt | 108,000 |
Net Cash | 3.17M |
Net Cash Per Share | $6.04 |
Equity (Book Value) | 1.21M |
Book Value Per Share | 2.29 |
Working Capital | 1.15M |
Full Balance Sheet Cash Flow
Operating Cash Flow | -8.14M |
Capital Expenditures | n/a |
Free Cash Flow | -8.14M |
FCF Per Share | -$15.50 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
GRI Bio does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | n/a |
Shareholder Yield | n/a |
Earnings Yield | -1,431.02% |
FCF Yield | -1,033.45% |
Analyst Forecast
The average price target for GRI Bio is $115.50, which is 7,600.00% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $115.50 |
Price Target Difference | 7,600.00% |
Analyst Consensus | Strong Buy |
Analyst Count | 2 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | -44.28% |
Stock Forecasts Stock Splits
The last stock split was on February 24, 2025. It was a reverse split with a ratio of 0.0588235:1.
Last Split Date | Feb 24, 2025 |
Split Type | Reverse |
Split Ratio | 0.0588235:1 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |